Provided by Tiger Trade Technology Pte. Ltd.

Tscan Therapeutics, Inc.

0.3145
-0.0030-0.94%
Post-market: 0.32000.0055+1.75%17:48 EDT
Volume:554.29K
Turnover:180.52K
Market Cap:21.32M
PE:-0.35
High:0.3450
Open:0.3222
Low:0.3145
Close:0.3175
52wk High:2.57
52wk Low:0.2902
Shares:67.78M
Float Shares:54.37M
Volume Ratio:0.87
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9000
EPS(LYR):-2.2805
ROE:-95.80%
ROA:-31.53%
PB:0.31
PE(LYR):-0.14

Loading ...

TScan Therapeutics - Strategic Reorganization Expected to Produce Cost Savings of $55 Mln Through End of 2027

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Announces Strategic Reorganization to Focus on in Vivo Cell Therapy for Solid Tumors

THOMSON REUTERS
·
Sep 02

TScan Therapeutics Faces Loss of Key Amgen Partnership

TIPRANKS
·
Aug 19

TScan Therapeutics - Amgen to Terminate Research Collaboration and License Agreement with TScan Therapeutics - SEC Filing

THOMSON REUTERS
·
Aug 19

Analysts Conflicted on These Healthcare Names: Alpha Cognition Inc (ACOG) and TScan Therapeutics (TCRX)

TIPRANKS
·
Aug 17

Atea Pharmaceuticals Q2 Loss Narrows as HCV Trial Expenses Decline

Reuters
·
Aug 13

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 12

TScan Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 12

TScan Therapeutics Q2 Net Income USD -30.359 Million

THOMSON REUTERS
·
Aug 12

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

TScan Therapeutics Inc Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 07

TScan Therapeutics Announces First Patient Dosed in Phase 3 Alloha-2™, a Pivotal Trial Evaluating Tsc-101 in Patients with Heme Malignancies

THOMSON REUTERS
·
Jul 29

Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)

TIPRANKS
·
Jun 23

TScan publishes ALLOHA Cohort C Phase 1 presentation for TSC-101 TCR-T therapy in post-transplant AML, ALL and MDS

Reuters
·
Jun 22

TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment

MT Newswires Live
·
Jun 22

TScan reports Phase 1 Cohort C data showing 11 of 14 patients reach complete donor chimerism after TSC-101 infusion

Reuters
·
Jun 22

TScan Therapeutics - on Track to Enroll First Patient in Phase 3 Alloha-2 Study of Tsc-101 This Month

THOMSON REUTERS
·
Jun 22

TScan Therapeutics Announces Positive Initial Data From Cohort C of Ongoing Alloha™ Phase 1 Study Evaluating Tsc-101 in Patients With Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

THOMSON REUTERS
·
Jun 22

TScan Therapeutics - Tsc-101 Continues to Be Well-Tolerated

THOMSON REUTERS
·
Jun 22